Search results for: Precision Medicine
Filter search results
OHE Lunchtime Seminar: An Overview of the US National Institutes of Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS®) and the PROMIS-Preference (PROPr) Scoring System
31 October 2018, 12:00am
OHE Lunchtime Seminar with Janel Hanmer, Assistant Professor of Medicine, University of Pittsburgh Medical Director, UPMC Patient Reported Outcomes Center. The EQ-5D, Health Utilities Index, SF-6D, and the Quality of…
The challenges and economics of drug development in 2022
1 July 2013
…be radically transformed as “precision” medicine plugs into the specific genetic makeup of both patients and diseases, and is paired with increasingly powerful and convenient diagnostics. 2. Innovation will be…
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
8 January 2020
Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…
OHE Models Future UK Medicines Spending for the ABPI
3 July 2012
…NHS expenditure on medicines. On 2 July, the ABPI released its projections for UK NHS medicines spending in the years to 2015 based on our model. The results project that…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…had an expressed goal of improving access to rare disease medicines, with most applying special considerations for orphan medicine reimbursement. However, rare disease medicines without orphan designations are typically not…
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
This research varies from other analyses in using a product-level, rather than a macro, approach. PharmacoEconomics has just published OHE’s study projecting medicines expenditure in the UK to 2015. (…
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
The German puzzle Discussion of Most-Favoured-Nation (MFN) drug pricing has converged on a single question: can the United States persuade other wealthy countries to pay more for medicines, and so…
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS. This OHE Consulting Report, published today, reviews “Measurement of Medicines Expenditure in the…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings. A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian…